Alcaraz-López JL, Bonilla-Zavala R, Luna-González J, Montes-Ledesma M, Sánchez-Huerta R, Chávez-Durán MA

Language: Spanish
References: 16
Page: 23-27
PDF size: 48.68 Kb.

ABSTRACT

A haemolytic transfusion reaction includes signs of red cell destruction following transfusion. Haemoglobinuria and jaundice are the most frequent. We carried out a retrospective study to determine the frequency of red phenotype cells in a multitransfused patient population who needed specific compatible red cells . In the course of screening tests we found that the frequency of the different erythrocyte antigens varied widely among the different groups of donors compared with patients from Mexico: ABO System, O Group = 72.0% vs 62.6%, Rh System = R1R1 = 26.4% vs 31.69%, R2R2 = 6.9% vs. 7.8% Rh negative = 2.9% vs 4.8%, Duffy-a = 15.0% vs 21.0% and Kidd-a = 18.0% vs 27.55. These results allow us to detect the relatively high frequency among patients compared with the donor population.

REFERENCES

1. Radillo-González A. Historia de la sangre En: Radillo-Gonzalez A. Medicina Transfusional, Editorial Prado. 2ª. Edición, México D.F. México 2006, p.1–22.

2. Rodríguez-Moyado R, Quintanar-García E y Mejía-Arregui M. Los Grupos Sanguíneos en la Población de la República Mexicana En: El Banco de Sangre y la Medicina Transfusional, Editorial Médica Panamericana, México D.F., México: 2004. p. 45–85.

3. García Gala JM, Vargas Pabon M, Rodríguez Vicente P, Ramírez Payer A, Rosón Porto C, Corte Buelga J R. Aloinmunización en pacientes politransfundidos. Sangre: 2004;39(6):417-421.

4. Coles SM, Kleins HG, and Holland PV. Alloinmunization in Two Multitransfused Patient Populations. Transfusion, 21(3)1981:462-466.

5. Fluit CRMG, Kunst VAJM, and Drenthe-Schonk AM. Incidente of red cell antibodies alter multiple blood transfusion. Transfusion, 30(6)1990:532-535.

6. Alcaraz López J L. Protocolo de manejo de las reacciones tranfusionales. Rev. Med. Inst. Mex. Seguro Soc. 43 (supl 1)2005:51–53.

7. Norma Oficial Mexicana NOM-003-SSA2-1993 para la disposición de sangre humana y sus componentes con fines terapéuticos. p. 38-40.

8. Recomendaciones para la Terapia Transfusional de Sangre y sus Componentes. Consenso de Expertos en Medicina Transfusional. Asociación Mexicana de Medicina Transfusional, A.C. Comité de Medicina Transfusional de la AMEH. México, D.F., México: 2003. p. 36-48.

9. Guía para el uso clínico de la sangre. Secretaría de Salud, Asociación Mexicana de Medicina Transfusiona, A.C. Agrupación Mexicana para el Estudio de la Hematología, A.C. México, D.F., México: 2007. p. 7–175.

10. Murphy MF. Practical Transfusion Medicine. London, United Kingdom: Blackwell Science Ltd; 2002. p. 147-156.

11. Robillard P, Nawei K. Four year cumulative incidence of serious adverse transfusion events in the Wuebec hemovigilance system. Inmunologic reactions to transfusion. Vox Sanguinis 2005;89(3):12-14.

12. Solinger A M, and Hess EV. Induction of autoantibodies by human immunodeficiency virus infection and their significance. Rheumatic Disease Clilnics of North America, 17(1)1991:157-176.

13. Editorial. Detecting alloantibodies in patients with autoantibodies. Transfusion, 39(1)1999:6-10.

14. Leger RM and Garratty G. Evaluation of methods for detecting alloantibodies underlying warm autoantibodies. Transfusion, 39(1)1999:11-16.

15. Mijovic A. Alloimmunization to RhD antigen in RhD-incompatible haemopoietic cell transpaltns with non-myeloablative condictioning. Vox Sanguinis, 83;2002:358-362.

16. Grunbaum BW, Crim M, Selvin S, Myhre BA, and Pace N. Distribution of genefrecuencies and discrimination probabilities for 22 human blood genetic systemsin four Racial Groups. Jurnal of forensic sciences, 25(2)1980:428-443.